Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: Does body weight matter?

American Journal of Hematology

Volumn 83, Issue 11, 2008, Pages 835-839

  Kanda, Yoshinobu ^a   Okamoto, Shinichiro ^b   Tauchi, Tetsuzo ^c   Kizaki, Masahiro ^d   Inokuchi, Koiti ^e   Yabe, Mariko ^b   Yokoyama, Kenji ^b   Ito, Yoshikazu ^c   Kimura, Yukihiko ^c   Higashihara, Masaaki ^f   Bessho, Masami ^g   Ando, Kiyoshi ^h   Chiba, Shigeru ⁱ   Kurokawa, Mineo ⁱ   Oshimi, Kazuo ^j   Dan, Kazuo ^e   Ohyashiki, Kazuma ^c   Ikeda, Yasuo ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

^e NIPPON MEDICAL SCHOOL   (Japan)

^f KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g SAITAMA MEDICAL UNIVERSITY   (Japan)

^h TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

^j JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; HYDROXYUREA; IMATINIB; INTERFERON;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BODY SIZE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COUGHING; CYTOGENETICS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EOSINOPHILIA; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; YOUNG ADULT;

EID: 55549127592     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21274     Document Type: Article

References (13)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-1340.
2. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550-554.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
4. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
5. Hochhaus A, Druker BJ, Larson RA, et al. IRIS 6-year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), treated with imatinib. Blood 2007;110:15A-16A (Abstract 25).
6. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820.
7. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children's Oncology Group phase 1 study. Blood 2004;104:2655-2660.
8. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: A subanalysis of the IRIS study. Blood 2008;111:4022-4028.
9. Larson RA, Druker BJ, Guilhot F, et al. Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib: An analysis of IRIS study data. Blood 2006;108:131a (Abstract 429).
10. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-3499.
11. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
12. Schmidli H, Peng B, Riviere GJ, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: Results of a phase III study. Br J Clin Pharmacol 2005;60:35-44.
13. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-1432.